Dr Ravi Diwan, MD | |
1820 State Route 33, Suite 4b, Neptune, NJ 07753-4860 | |
(732) 776-8500 | |
(732) 776-8946 |
Full Name | Dr Ravi Diwan |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 18 Years |
Location | 1820 State Route 33, Neptune, New Jersey |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376792382 | NPI | - | NPPES |
03643116 | Medicaid | NY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 255642 (New York) | Secondary |
207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA09273100 (New Jersey) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Riverview Medical Center | Red bank, NJ | Hospital |
Bayshore Medical Center | Holmdel, NJ | Hospital |
Jersey Shore University Medical Center | Neptune, NJ | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Shore Heart Group, Pa | 1557268448 | 34 |
Meridian Cardiovascular Interpretive Services Pc | 8527012236 | 32 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Plasmodium falciparum, the most lethal malaria parasite, is a housebreaking villain of the red blood cell world. Like a burglar searching for a way in to his targeted premises, the parasite explores a variety of potential entry points to invade the red blood cells of its human victims. When a weak point is found, the intrusion proceeds.
› Verified 4 days ago
Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Plasmodium falciparum, the most lethal malaria parasite, is a housebreaking villain of the red blood cell world. Like a burglar searching for a way in to his targeted premises, the parasite explores a variety of potential entry points to invade the red blood cells of its human victims. When a weak point is found, the intrusion proceeds.
› Verified 4 days ago
Entity Name | Shore Heart Group, Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063466605 PECOS PAC ID: 1557268448 Enrollment ID: O20031218000083 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Plasmodium falciparum, the most lethal malaria parasite, is a housebreaking villain of the red blood cell world. Like a burglar searching for a way in to his targeted premises, the parasite explores a variety of potential entry points to invade the red blood cells of its human victims. When a weak point is found, the intrusion proceeds.
› Verified 4 days ago
Entity Name | Meridian Cardiovascular Interpretive Services Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548310576 PECOS PAC ID: 8527012236 Enrollment ID: O20050307000039 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Plasmodium falciparum, the most lethal malaria parasite, is a housebreaking villain of the red blood cell world. Like a burglar searching for a way in to his targeted premises, the parasite explores a variety of potential entry points to invade the red blood cells of its human victims. When a weak point is found, the intrusion proceeds.
› Verified 4 days ago
Entity Name | Sovereign Medical Group Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1710282082 PECOS PAC ID: 1456535392 Enrollment ID: O20110418000519 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Plasmodium falciparum, the most lethal malaria parasite, is a housebreaking villain of the red blood cell world. Like a burglar searching for a way in to his targeted premises, the parasite explores a variety of potential entry points to invade the red blood cells of its human victims. When a weak point is found, the intrusion proceeds.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Ravi Diwan, MD 1820 State Route 33, Suite 4b, Neptune, NJ 07753-4860 Ph: (732) 776-8500 | Dr Ravi Diwan, MD 1820 State Route 33, Suite 4b, Neptune, NJ 07753-4860 Ph: (732) 776-8500 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Plasmodium falciparum, the most lethal malaria parasite, is a housebreaking villain of the red blood cell world. Like a burglar searching for a way in to his targeted premises, the parasite explores a variety of potential entry points to invade the red blood cells of its human victims. When a weak point is found, the intrusion proceeds.
› Verified 4 days ago
Hani Naser, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-776-4483 Fax: 732-776-4798 | |
Dr. Adam Chaim Kaplan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 19 Davis Ave Fl 6, Neptune, NJ 07753 Phone: 732-897-3990 Fax: 732-897-3997 | |
Jose Fune, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 19 Davis Ave Fl 6, Neptune, NJ 07753 Phone: 732-897-3995 Fax: 732-897-3997 | |
Dr. Daniel Mark Shenouda, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 908-217-3023 Fax: 732-776-4798 | |
Dr. Kathleen King Casey, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 19 Davis Ave Fl 6, Neptune, NJ 07753 Phone: 732-897-3995 Fax: 732-897-3997 | |
Philip Willie Bankole Clarkson, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-776-4483 Fax: 732-776-4798 | |
Kelly West Fitzpatrick, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 19 Davis Ave Fl 2, Neptune, NJ 07753 Phone: 732-367-1535 Fax: 732-367-9514 |